New data presented at DDW 2022 show nearly twofold risk of loss of remission in ulcerative colitis patients with histological inflammation at baseline biopsy

DURHAM, NCMay 22, 2022 /PRNewswire/ — New data shows that more than a third (36.6%) of ulcerative colitis (UC) patients who responded to advanced therapies experienced a loss of remission (LOR) in their symptom control, often within a year. The analysis of Target RWE’s TARGET-IBD large, longitudinal cohort, Inflammation on index biopsy predicts loss of remission in patients with ulcerative colitis with endoscopic remission: a US cohort analysis† [Su1537] was presented today by Benjamin ClickMD, associate professor of medicine, division of gastroenterology and hepatology, University of Colorado School of Medicine, at the Digestive Disease Week in San Diego

Target RWE Health Evidence Solutions logo (PRNewsfoto/Target RWE)

Target RWE’s IBD study and real-world data presented at DDW 2022 include more than 500 patients with ulcerative colitis.

The study found that in patients in endoscopic remission, histologic inflammation was associated with a two-fold increased risk of subsequent LOR.

“While drugs for UC induce remission for a portion of patients, unfortunately we often see a recurrence of disease activity and symptoms over time,” said Dr. click. “We sought to discover factors that predict relapse and found that histological inflammation despite endoscopic remission is an important risk factor for later LOR. Future research should focus on determining whether treatment modification or intensification may be effective in preventing LOR in certain patients.”

The Target RWE study included 513 UC patients eligible for analysis (53.0% female; median age at diagnosis 31 years; median disease duration 10 years). Corticosteroid-free adult UC patients in endoscopic remission at index colonoscopy (no evidence of endoscopic inflammation, erosions, or ulceration), with an index histology assessment and known disease duration, who participated in TARGET-IBD of july 2017 until June 2021, were included. LOR was defined as the presence of endoscopic inflammation, erosion, or ulceration at follow-up colonoscopy or steroid initiation.

TARGET-IBD is a five-year longitudinal observational study in more than 4,900 adult and pediatric patients (aged two years and older) undergoing therapy for IBD, including UC and Crohn’s disease, at academic and community centers in the US. Field data is collected from approved participants, who may also provide patient-reported outcome measures and biospecimens. Read more about TARGET-IBD publications here.

The Crohn’s and Colitis Foundation of America estimates that more than 900,000 Americans are living with UC.1 Crohn’s disease and UC are often followed together because they are both considered inflammatory bowel disease (IBD). UC is found in the large intestine (colon) and rectum, while Crohn’s disease can be found anywhere in the gastrointestinal tract, from the mouth to the anus.1 Chronic inflammation from IBD damages the GI tract, so it’s important to determine who is most at risk for LOR. The US Centers for Disease Control and Prevention estimate that the prevalence of IBD has increased significantly in the US over the past two decades.2


As the industry’s best, complete Real World Evidence solution, Target RWE is a distinctly collaborative enterprise that unites Real World datasets and advanced RWE analytics into an integrated community, changing the healthcare paradigm for how decisions are made to improve lives.

Target RWE uses unique, connected datasets across multiple therapeutic areas that represent detailed data from a variety of patients in academic and community settings. Our rigorous, interactive, and advanced Real World Evidence analytics extract deep insights from Real World Data to answer the most complex questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unparalleled community of key opinion leaders, patients and healthcare stakeholders in a collaborative and dynamic model. For more information, visit


Kayla Slake
Marketing Manager

[email protected]

984.234.0268 ext 205



View original content to download multimedia: remission-in-ulcerative-colitis-patients-who had-histological-inflammation-on-baseline-biopsy-301552421.html


Leave a Comment